Resultados: 3

Regulatory T cell abundance and activation status before and after priming with HIVIS-DNA and boosting with MVA-HIV/rgp140/GLA-AF may impact the magnitude of the vaccine-induced immune responses

Immunobiol., Suppl; 223 (12), 2018
Little is known about regulatory CD4 T cells (Tregs) in the context of HIV vaccines. Tregs can be differentiated into resting (FoxP3+CD45RA+ - rTregs), activated (FoxP3HighCD45RA- - aTregs) and memory (FoxP3LowCD45RA- - mTregs). Tregs, as CD4 T cells, are also frequent targets for HIV infection. We studi...

Optimizing the immunogenicity of HIV prime-boost DNA-MVA-rgp140/GLA vaccines in a phase II randomized factorial trial design

PLos ONE; 13 (11), 2018
Background: We evaluated the safety and immunogenicity of (i) an intradermal HIV-DNA regimen given with/without intradermal electroporation (EP) as prime and (ii) the impact of boosting with modified vaccinia virus Ankara (HIV-MVA) administered with or without subtype C CN54rgp140 envelope protein adjuva...

Intradermal HIV-1 DNA immunization using needle-free zetajet injection followed by HIV-modified Vaccinia virus ankara vaccination is safe and immunogenic in Mozambican young adults: A Phase i randomized controlled trial

AIDS res. hum. retrovir; 34 (2), 2018
According to UNAIDS, there were a total of 36.7 million people living with HIV and 2.1 million new infections in 2015. Eastern and Southern Africa continues to be most severely affected, accounting for 51.7% of the total global infections. Antiretroviral therapy has contributed to slowing the HIV epidemi...